WO2025079025 - IDES-RAPAMYCIN CONJUGATE IN AAV GENE THERAPY
National phase entry is expected:
Publication Number
WO/2025/079025
Publication Date
17.04.2025
International Application No.
PCT/IB2024/059972
International Filing Date
11.10.2024
Title **
[English]
IDES-RAPAMYCIN CONJUGATE IN AAV GENE THERAPY
[French]
CONJUGUÉ IDES-RAPAMYCINE DANS UNE THÉRAPIE GÉNIQUE AAV
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
KHAN, Tayeba
KENNISTON, Jon A.
NATARAJAN, Madhusudan
PALLISER, Deborah
LEE, Hong Myung
RICE, Elise
WATTERS, Alexander L.
PAPAIOANNOU, Nikolaos
Priority Data
63/590,195
13.10.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4270 | |
| EPO | Filing, Examination, Granting | 47143 | |
| Japan | Filing, Examination, Granting | 3692 | |
| South Korea | Filing, Examination, Granting | 5075 | |
| USA | Filing, Examination, Granting | 13990 |
Total:
74,170
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
., rapamycin, for immunosuppression in applications such as gene therapy. The present disclosure also provides methods of synthesis of conjugates and methods of conjugation (i.e. sortase-mediated conjugation) of payloads to IdeS or IdeZ for use in such applications.[French]
La présente invention concerne également des procédés de synthèse de conjugués et des procédés de conjugaison (c'est-à-dire de conjugaison à médiation par sortase) de charges utiles à IdeS ou IdeZ à utiliser dans de telles applications.